DC-Ad-CCL-21 intratumoral therapy (UCLA/Department of Veterans Affairs)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDC-Ad-CCL-21 intratumoral therapy (UCLA/Department of Veterans Affairs)
Drug Alias NameDC-AdCCL21Ad-CCL21-DCDC-Ad-CCL-21
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionCXC chemokine receptor modulators
TargetsCXC chemokine receptor
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDepartment Of Veterans AffairsUniversity Of California At Los Angeles
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California At Los AngelesDepartment Of Veterans Affairs
Inactive CompaniesNational Cancer Institute
Active IndicationsLung Neoplasms
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A